Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression

被引:24
|
作者
Bolon, I [1 ]
Zhou, HM [1 ]
Charron, Y [1 ]
Wohlwend, A [1 ]
Vassalli, JD [1 ]
机构
[1] Univ Geneva, Ctr Med, Sch Med, Dept Morphol, CH-1211 Geneva 4, Switzerland
来源
AMERICAN JOURNAL OF PATHOLOGY | 2004年 / 164卷 / 06期
关键词
D O I
10.1016/S0002-9440(10)63786-8
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Increased expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) is associated with different pathological conditions. Both uPAR-mediated signaling and plasmin-catalyzed extracellular proteolysis may contribute to pathogenesis. To evaluate the involvement of plasminogen in such circumstances, we have taken advantage of transgenic mouse models in which overexpression of uPA and/or uPAR in enamel epithelium, basal epidermis, and hair follicles leads to a pathological phenotype; uPA transgenic mice have chalky-white incisors and, when uPAR is co-expressed, develop extensive alopecia, epidermal thickening, and subepidermal blisters. We report here that when these transgenic mice were backcrossed into a plasminogen-deficient (Plg(-/-)) background, the dental and skin phenotypes appeared completely normal. Heterozygous Plg+/- transgenic mice exhibited a haplo-insufficiency, with an intermediate or normal phenotype. These results do not argue in favor of a role for uPAR-mediated signaling in our experimental model; rather, they demonstrate an essential, dose-dependent, requirement for plasminogen in uPA-mediated tissue alterations. They also support the hypothesis that plasminogen could play a part in certain skin diseases.
引用
收藏
页码:2299 / 2304
页数:6
相关论文
共 50 条
  • [31] THE CHICKEN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR GENE
    LESLIE, ND
    KESSLER, CA
    BELL, SM
    DEGEN, JL
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1990, 265 (03) : 1339 - 1344
  • [32] A CELLULAR RECEPTOR FOR UROKINASE-TYPE PLASMINOGEN-ACTIVATOR
    BELIN, D
    BACCINO, D
    WOHLWEND, A
    ESTREICHER, A
    HUARTE, J
    VASSALLI, JD
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 46 - 46
  • [33] Elucidating novel urokinase-type plasminogen activator inhibitors
    Smith, E.
    Spencer, J.
    Ali, M.
    Abdinejad, M.
    Kankanala, J.
    Fishwick, C.
    Philippou, H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (06) : E18 - E18
  • [34] Elucidating novel urokinase-type plasminogen activator inhibitors
    Smith, E. L.
    John, S.
    Abdinejad, M.
    Kankanala, J.
    Fishwick, C. W. G.
    Philippou, E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 819 - 819
  • [35] Urokinase-type plasminogen activator in carcinomatous pleural fluid
    Ishikawa, H
    Satoh, H
    Hasegawa, S
    Yazawa, T
    Naito, T
    Yamashita, YT
    Ohtsuka, M
    Ogata, T
    Kamma, H
    EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (07) : 1566 - 1571
  • [36] Urokinase-Type Plasminogen Activator Inhibits Efferocytosis of Neutrophils
    Yang, Yanping
    Friggeri, Arnaud
    Banerjee, Sami
    Bdeir, Khalil
    Cines, Douglas B.
    Liu, Gang
    Abraham, Edward
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 182 (12) : 1516 - 1523
  • [37] Properties of the Urokinase-Type Plasminogen Activator Modified with Phenylglyoxal
    L. I. Moukhametova
    R. B. Aisina
    G. Yu. Lomakina
    S. D. Varfolomeev
    Russian Journal of Bioorganic Chemistry, 2002, 28 : 278 - 283
  • [38] Urokinase-type plasminogen activator in human gliomas in vitro
    Gillespie, J
    McCormick, D
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1996, 22 (05) : 454 - 454
  • [39] Role of urokinase-type plasminogen activator in local immunotherapy
    Takeda, T
    Ito, Y
    Wakasugi, E
    Kobayashi, T
    Monden, M
    ONCOLOGY REPORTS, 1998, 5 (02) : 329 - 333
  • [40] The urokinase-type plasminogen activator and its receptor in cancer
    Rosenberg, S
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 34, 1999, 34 : 121 - 128